| Metallo-β-lactamases: a last frontier for β-lactams? G Cornaglia, H Giamarellou, GM Rossolini The Lancet infectious diseases 11 (5), 381-393, 2011 | 927 | 2011 |
| Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe M Souli, I Galani, H Giamarellou Eurosurveillance 13 (47), 2008 | 728 | 2008 |
| International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical … BT Tsuji, JM Pogue, AP Zavascki, M Paul, GL Daikos, A Forrest, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39 (1 …, 2019 | 692 | 2019 |
| Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram … D Plachouras, M Karvanen, LE Friberg, E Papadomichelakis, ... Antimicrobial agents and chemotherapy 53 (8), 3430-3436, 2009 | 624 | 2009 |
| Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective … B Gutiérrez-Gutiérrez, E Salamanca, M de Cueto, PR Hsueh, P Viale, ... The Lancet Infectious Diseases 17 (7), 726-734, 2017 | 479 | 2017 |
| An Outbreak of Infection due to β-Lactamase Klebsiella pneumoniae Carbapenemase 2–Producing K. pneumoniae in a Greek University Hospital: Molecular … M Souli, I Galani, A Antoniadou, E Papadomichelakis, G Poulakou, ... Clinical infectious diseases 50 (3), 364-373, 2010 | 437 | 2010 |
| Multidrug-resistant Gram-negative infections: what are the treatment options? H Giamarellou, G Poulakou Drugs 69, 1879-1901, 2009 | 422 | 2009 |
| Acinetobacter baumannii: a universal threat to public health? H Giamarellou, A Antoniadou, K Kanellakopoulou International journal of antimicrobial agents 32 (2), 106-119, 2008 | 421 | 2008 |
| Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial LPG Derde, BS Cooper, H Goossens, S Malhotra-Kumar, RJL Willems, ... The Lancet infectious diseases 14 (1), 31-39, 2014 | 407 | 2014 |
| Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches I Karaiskos, H Giamarellou Expert opinion on pharmacotherapy 15 (10), 1351-1370, 2014 | 401 | 2014 |
| Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control Y Carmeli, M Akova, G Cornaglia, GL Daikos, J Garau, S Harbarth, ... Clinical Microbiology and Infection 16 (2), 102-111, 2010 | 365 | 2010 |
| Health care–associated native valve endocarditis: importance of non-nosocomial acquisition N Benito, JM Miro, E De Lazzari, CH Cabell, A Del Rio, J Altclas, ... Annals of internal medicine 150 (9), 586-594, 2009 | 337 | 2009 |
| Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster A Antoniadou, F Kontopidou, G Poulakou, E Koratzanis, I Galani, ... Journal of Antimicrobial Chemotherapy 59 (4), 786-790, 2007 | 324 | 2007 |
| Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill AF Mohamed, I Karaiskos, D Plachouras, M Karvanen, K Pontikis, ... Antimicrobial agents and chemotherapy 56 (8), 4241-4249, 2012 | 309 | 2012 |
| Multidrug-resistant Gram-negative bacteria: how to treat and for how long H Giamarellou International journal of antimicrobial agents 36, S50-S54, 2010 | 291 | 2010 |
| Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing … K Pontikis, I Karaiskos, S Bastani, G Dimopoulos, M Kalogirou, M Katsiari, ... International journal of antimicrobial agents 43 (1), 52-59, 2014 | 285 | 2014 |
| Characterization of the plasmidic beta-lactamase CMY-2, which is responsible for cephamycin resistance A Bauernfeind, I Stemplinger, R Jungwirth, H Giamarellou Antimicrobial agents and chemotherapy 40 (1), 221-224, 1996 | 267 | 1996 |
| Community-acquired methicillin-resistant Staphylococcus aureus infections HC Maltezou, H Giamarellou International journal of antimicrobial agents 27 (2), 87-96, 2006 | 266 | 2006 |
| Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? EJ Giamarellos-Bourboulis, A Mega, P Grecka, N Scarpa, G Koratzanis, ... Intensive care medicine 28, 1351-1356, 2002 | 245 | 2002 |
| Central nervous system manifestations of Mycoplasma pneumoniae infections S Tsiodras, I Kelesidis, T Kelesidis, E Stamboulis, H Giamarellou Journal of Infection 51 (5), 343-354, 2005 | 243 | 2005 |
